Olanzapine drug data and news

---

Psychosis Onset May Be Delayed By Olanzapine  May 2, 2006
For young people who seem to be developing early signs of schizophrenia, early treatment with the antipsychotic drug olanzapine appears to delay the rate of ... - Medical News Today (press release),

Randomized, Double-Blind Trial of Olanzapine Versus Placebo in ...  May 2, 2006
OBJECTIVE: This study assessed the efficacy of olanzapine in delaying or preventing conversion to psychosis and reducing symptoms in people with prodromal ... - Am J Psychiatry (subscription)

Olanzapine appears to lower or delay full-blown psychosis  May 3, 2006
For young people who clearly seem to be developing early signs of schizophrenia, treatment with the antipsychotic drug olanzapine appears to lower or delay the ... - News-Medical.net,

Innovations: Geriatric Psychiatry: Diagnosis and Treatment of ...  May 10, 2006
...in JAMA (3), cite the modest but significant reductions in neuropsychiatric symptoms demonstrated among elderly patients treated with risperidone or olanzapine ... - Psychiatric Services (subscription)

Understanding and Managing Psychosis in Late Life  May 15, 2006
For older patients with schizophrenia or psychosis of AD, risperidone (Risperdal), olanzapine (Zyprexa) and quetiapine (Seroquel) are currently the three most ... - Psychiatric Times,

Patient Management Exercise FOR PSYCHOTHERAPY  May 15, 2006
According to his self-reported history, he had trials of fluoxetine, paroxetine, lithium, divalproex, haloperidol, olanzapine, risperidone, clonazepam ... - Focus (subscription)

Recent Developments in Antipsychotic Use in Adults  Apr 20, 2006
Also reviewed is information about a new intramuscular (IM) formulation of olanzapine (Zyprexa) and an indication for clozapine (Clozaril) recently approved by ... - Psychiatric Times,

In This Issue  May 2, 2006
The Prevention Through Risk Identification, Management, and Education (PRIME) study points to a possible role for olanzapine. People ... - Am J Psychiatry (subscription)

Onset of Psychosis May Be Delayed by Medication  May 1, 2006
May 1, 2006--For young people who clearly seem to be developing early signs of schizophrenia, treatment with the antipsychotic drug olanzapine appears to lower ... - PharmaLive.com (press release),

Corcept Therapeutics Announces First Quarter 2006 Results  May 9, 2006
The company has also initiated a proof-of-concept study to evaluate the ability of CORLUX to mitigate weight gain associated with the use of olanzapine. ... - MSN Money

Lilly to Extend Patient Assistance Programs for Medicare Patients  May 10, 2006
...would allow Lilly to continue providing Forteo(R) (teriparatide [rDNA origin] injection), a treatment for osteoporosis, and Zyprexa(R) (olanzapine, Lilly), a ... - PR Newswire (press release),

Have you taken Zyprexa and developed diabetes?Information and news ...  May 5, 2006
Zyprexa is the product name for Olanzapine,it is Lilly's top selling drug.It was approved by the FDA in 1996 ,an 'atypical' antipsychotic a newer class of ... - MediaSyndicate (press release)

Psychiatric Decision Making in the Adoption of a New Antipsychotic ...  May 4, 2006
Woodward ND, Purdon SE, Meltzer HY, et al: A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. ... - Psychiatric Services (subscription)

Zyprexa may delay psychosis in at-risk patients  May 2, 2006
Moreover, in the year after treatment stopped, the patients who had taken olanzapine experienced increasing symptoms and a third went on to become psychotic ... - Pharma Times (subscription),

Treating early signs of schizophrenia advised  May 1, 2006
38 percent of those on a placebo developed psychosis - delusional thinking or hallucinations - compared with 16 percent of those taking olanzapine, made by Eli ... - Baltimore Sun,

Lilly to extend patient assistance programs for Medicare patients  May 11, 2006
...the OIG would allow Lilly to continue providing Forteo (teriparatide [rDNA origin] injection), a treatment for osteoporosis, and Zyprexa (olanzapine, Lilly), a ... - News-Medical.net,

Hallucinations in Children and Adolescents: Considerations in the ...  May 2, 2006
A prodromal trial of olanzapine was successful in reducing the conversion to psychosis to 25%, compared to the follow-along group rate of 50% (19). ... - Am J Psychiatry (subscription)

Behavioral and Pharmacologic Treatment of Aggression in Children ...  May 10, 2006
Clozapine (Clozaril), quetiapine (Seroquel), olanzapine (Zyprexa) and ziprasidone (Geodon) have been evaluated in small or uncontrolled studies and case ... - Psychiatric Times,

Department of Ambulatory Care and Prevention, Harvard Medical ...  May 2, 2006
Bobes, J., Gilbert, J., Ciudad, A., et al (2003) Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first ... - British Journal of Psychiatry (subscription),

Lilly to Extend Patient Assistance Programs for Medicare Patients  May 10, 2006
OIG would allow Lilly to continue providing Forteo® (teriparatide [rDNA origin] injection), a treatment for osteoporosis, and Zyprexa® (olanzapine, Lilly), a ... - Yahoo! News (press release)

Lilly Reports Q1 EPS of $.77, or 13% Growth  Apr 20, 2006
DNA origin, Lilly) Prozac(R) (fluoxetine hydrochloride, Dista) Strattera(R) (atomoxetine hydrochloride, Lilly) Symbyax(R) (olanzapine fluoxetine combination ... - MSN Money

Antipsychotic Drug Use Growing Fastest Among Children  May 2, 2006
Children are receiving the latest generation of antipsychotics - known as atypical antipsychotics, including risperidone, olanzapine, clozapine, ziprasidone ... - YubaNet,

Zyprexa Trial in Schizophrenia 'Prodome' Yields Only Hints  May 3, 2006
NEW HAVEN, Conn., May 3 — A two-year study of Zyprexa (olanzapine) in patients thought to have early signs of schizophrenia had mixed results, researchers ... - MedPage Today,

Miller, Mohammed win courage awards  May 4, 2006
Over a period of four years, she made three serious suicide attempts. Finally, she took the drug olanzapine and the voices stopped. ... - Burnaby Newsleader,

WAS STUDY UNETHICAL?  May 5, 2006
...also cite a report in the American Journal of Psychiatry, of a study of adolescents being given the antipsychotic drug, Zyprexa (olanzapine), although they had ... - Free Market News Network,

Knives found before nurse was stabbed  Apr 28, 2006
...room. Concerns had already been raised about his unstable behaviour, and he had been placed on the anti-psychotic drug olanzapine. ... - Leeds Today,

Schizophrenia gene function offers hope for drug R&D  Apr 23, 2006
The newer atypical antipsychotic medications (such as clozapine, risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole) are usually preferred over ... - DrugResearcher.com,

Antiparkinsonian prescription and extrapyramidal symptoms  Apr 28, 2006
Tran, PV, Hamilton, SH, Kuntz, AJ, et al (1997) Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic ... - British Journal of Psychiatry (subscription),

Treatment Challenges in Schizophrenia: A Multifaceted Approach to ...  Apr 17, 2006
18 According to the American Diabetes Association (ADA) consensus statement, 19 clozapine and olanzapine (Zyprexa) appear to cause the greatest amount of ... - Psychiatric Times,

The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of olanzapine, caution should be used when olanzapine is taken in combination with other centrally acting drugs and alcohol.

Because of its potential for inducing hypotension, olanzapine may enhance the effects of certain antihypertensive agents. Olanzapine may antagonize the effects of levodopa and dopamine agonists.

The Effect of Other Drugs on Olanzapine ó Agents that induce CYP1A2 or glucuronyl transferase enzymes, such as omeprazole and rifampin, may cause an increase in olanzapine clearance. Inhibitors of CYP1A2 could potentially inhibit olanzapine clearance. Although olanzapine is metabolized by multiple enzyme systems, induction or inhibition of a single enzyme may appreciably alter olanzapine clearance. Therefore, a dosage increase (for induction) or a dosage decrease (for inhibition) may need to be considered with specific drugs.

Charcoal ó The administration of activated charcoal (1 g) reduced the Cmax and AUC of olanzapine by about 60%. As peak olanzapine levels are not typically obtained until about 6hours after dosing, charcoal may be a useful treatment for olanzapine overdose.

Cimetidine and Antacids ó Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.

Carbamazepine ó Carbamazepine therapy (200 mg bid) causes an approximately 50% increase in the clearance of olanzapine. This increase is likely due to the fact that carbamazepine is a potent inducer of CYP1A2 activity. Higher daily doses of carbamazepine may cause an even greater increase in olanzapine clearance.

Ethanol ó Ethanol (45mg/70kg singledose) did not have an effect on olanzapine pharmacokinetics.

Fluoxetine ó Fluoxetine (60 mg single dose or 60 mg daily for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. The magnitude of the impact of this factor is small in comparison to the overall variability between individuals, and therefore dose modification is not routinely recommended.

Fluvoxamine ó Fluvoxamine, a CYP1A2 inhibitor, decreases the clearance of olanzapine. This results in a mean increase in olanzapine Cmax following fluvoxamine of 54% in female nonsmokers and 77% in male smokers. The mean increase in olanzapine AUC is 52% and 108%, respectively. Lower doses of olanzapine should be considered in patients receiving concomitant treatment with fluvoxamine.

Warfarin ó Warfarin (20mg singledose) did not affect olanzapine pharmacokinetics.

Effect of Olanzapine on Other Drugs ó In vitro studies utilizing human liver microsomes suggest that olanzapine has little potential to inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A. Thus, olanzapine is unlikely to cause clinically important drug interactions mediated by these enzymes.

Lithium ó Multiple doses of olanzapine (10 mg for 8 days) did not influence the kinetics of lithium. Therefore, concomitant olanzapine administration does not require dosage adjustment of lithium.

Valproate ó Studies in vitro using human liver microsomes determined that olanzapine has little potential to inhibit the major metabolic pathway, glucuronidation, of valproate. Further, valproate has little effect on the metabolism of olanzapine in vitro. In vivo administration of olanzapine (10 mg daily for 2 weeks) did not affect the steady state plasma concentrations of valproate. Therefore, concomitant olanzapine administration does not require dosage adjustment of valproate.

Single doses of olanzapine did not affect the pharmacokinetics of imipramine or its active metabolite desipramine, and warfarin. Multiple doses of olanzapine did not influence the kinetics of diazepam and its active metabolite N-desmethyldiazepam, ethanol, or biperiden. However, the co-administration of either diazepam or ethanol with olanzapine potentiated the orthostatic hypotension observed with olanzapine. Multiple doses of olanzapine did not affect the pharmacokinetics of theophylline or its metabolites.